Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Latest from Vanderbilt-Ingram Cancer Center


Dr Grieb on MYC in CRC

May 18, 2023

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors. 

Dr Gibson on Advancements in Biomarker Identification in Gastric/GEJ Adenocarcinoma

May 15, 2023

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis

April 11, 2023

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.